GFC.BK Genesis Fertility Center Public Company Limited
- Market cap
- THB 438M
- P/E
- -
- P/B
- 0.82x
- ROE
- -1.2%
- Dividend yield
- 9.05%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GFC.BK undervalued?
Graham numberThe Graham number of Genesis Fertility Center Public Company Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genesis Fertility Center Public Company Limited fundamental analysis
No fundamental analysis for Genesis Fertility Center Public Company Limited yet.
Genesis Fertility Center Public Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genesis Fertility Center Public Company Limited
Genesis Fertility Center Public Company Limited operates as a medical clinic focusing on treating infertility in Thailand. The company offers intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF), intrauterine insemination (IUI), frozen embryo transfer, egg freezing, and chromosomal screening services, as well as counseling services to infertile people. It is also involved in the provision of other businesses consulting and management investment services. Gen…
Full company profileGenesis Fertility Center Public Company Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genesis Fertility Center Public Company Limited annual financial statements (THB; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 242M | 276M | 355M | 372M | 353M | 279M |
| Gross Profit | 119M | 130M | 172M | 178M | 147M | 107M |
| Operating Income | 86.7M | 82.2M | 103M | 94.2M | 34.8M | -178K |
| EBITDA | - | 96.8M | 117M | 114M | 84.1M | 39.1M |
| Net Income | 69.6M | 65.7M | 77.5M | 73.5M | 22.4M | -6.64M |
| EPS | 0.32 | 0.30 | 0.35 | 0.33 | 0.10 | -0.03 |
| Balance Sheet | ||||||
| Total Assets | 190M | 408M | 641M | 726M | 671M | 621M |
| Total Liabilities | 66.0M | 254M | 74.5M | 124M | 81.7M | 66.0M |
| Shareholders' Equity | 124M | 154M | 561M | 584M | 568M | 534M |
| Cash & Short-term Investments | 97.5M | 85.4M | 309M | 158M | 131M | 98.3M |
| Cash Flow | ||||||
| Operating Cash Flow | 91.4M | 82.7M | 98.7M | 110M | 63.9M | 46.2M |
| Capital Expenditure | 6.90M | 236M | 11.9M | 214M | 11.8M | 5.34M |
| Free Cash Flow | 84.5M | -153M | 86.9M | -104M | 52.0M | 40.8M |
| Ratios | ||||||
| ROE | 56.3% | 42.5% | 13.8% | 12.6% | 3.9% | -1.2% |
| ROA | 36.7% | 16.1% | 12.1% | 10.1% | 3.3% | -1.1% |
| Net Profit Margin | 28.8% | 23.8% | 21.9% | 19.8% | 6.3% | -2.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Genesis Fertility Center Public Company Limited dividends
- Dividend yield
- 9.05%
- Forward dividend
- 0.13 THB
- Payout ratio
- 176.8%
- Ex-dividend date
- Aug 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | THB 39.6M | 0.18 | 176.8% |
| 2024 | THB 50.6M | 0.23 | 68.8% |
| 2023 | THB 73.0M | 0.33 | 94.2% |
| 2022 | THB 35.0M | 0.16 | 53.3% |
| 2021 | THB 70.0M | 0.32 | 100.5% |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Genesis Fertility Center Public Company Limited
- Insiders 83.38%
- Institutions 0.00%
- Public & others 16.62%
- Shares outstanding 220M
- Free float 69.1M
Genesis Fertility Center Public Company Limited company profile
- Company name
- Genesis Fertility Center Public Company Limited
- Ticker
- GFC.BK
- Exchange
- Thailand Exchange
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Fiscal year end
- September
- Address
- No. 2292, Rama 9 Road, Bangkok, Thailand, 10250
- Phone
- 66 97 484 5335
- Website
- genesisfertilitycenter.co.th
About Genesis Fertility Center Public Company Limited
Genesis Fertility Center Public Company Limited operates as a medical clinic focusing on treating infertility in Thailand. The company offers intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF), intrauterine insemination (IUI), frozen embryo transfer, egg freezing, and chromosomal screening services, as well as counseling services to infertile people. It is also involved in the provision of other businesses consulting and management investment services. Genesis Fertility Center Public Company Limited was founded in 2016 and is headquartered in Bangkok, Thailand.
Genesis Fertility Center Public Company Limited management
6- Dr. Porrawan TangthamDirector & Director of Medical and Nursing Services · born 1983
- Ms. Piyada WiratpongChief Laboratory Officer & Director · born 1970
- Mr. Nathee Tungchitsodsai BPHARMChief Executive Officer · born 1971
- Mr. Amorn TrairatassawaChief Accounting & Finance Officer and Company Secretary · born 1978
- Dr. Chutima SriritChief Operations Officer · born 1982
- Ms. Ajjhamaporn NaowasuwanDirector of Sales & Marketing